PRGN-3006 Adoptive Cellular Therapy
A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients With CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome
More Information
- Trial Status
- Active, Not Recruiting
- Trial Phase
- Phase 1
- Enrollment
- 88 patients (estimated)
- Sponsors
- Precigen, Inc
- Tags
- CAR T Cell, CD33
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1522
- NCT Identifier
- NCT03927261
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.